NCT03928158 is a Phase 2 clinical trial of LCZ 696 in Heart Failure, sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation.

What drugs are being tested in NCT03928158?

Interventions in NCT03928158: LCZ 696, Valsartan.

What condition does NCT03928158 study?

NCT03928158 studies Heart Failure, Essential Hypertension.

Is NCT03928158 still recruiting?

NCT03928158 is currently completed. Last updated 25 May 2025.

Last reviewed 2025-05-25 · How we verify

NCT03928158

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LCZ696 in Advanced LV Hypertrophy and HFpEF

Completed Phase 2 Last updated 25 May 2025

What this trial tests

Phase 2 trial testing LCZ 696 in Heart Failure in 61 participants. Completed in 31 December 2023.

Timeline

31 May 2019

Primary endpoint
30 June 2023

31 December 2023

Quick facts

Lead sponsor	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	61
Start date	31 May 2019
Primary completion	30 June 2023
Estimated completion	31 December 2023
Sites	1 location across Russia

Drugs / interventions tested

LCZ 696 — full drug profile →
Valsartan (VALSARTAN) — full drug profile →

Conditions studied

Heart Failure — all drugs for Heart Failure →
Essential Hypertension — all drugs for Essential Hypertension →

Sponsor

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Who can join

Adults 40 to 80, any sex, with Heart Failure or Essential Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with advanced LVH and HFpEF will be randomly assigned in open-label fashion to receive LCZ696 titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily, and will be treated for 24 weeks.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N, Manoharan K, Davies C, Lumbers RT. · · 2021 · cited 39× · PMID 34022072 · DOI 10.1002/14651858.cd012721.pub3
The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies.
Cai Z, Wu C, Xu Y, Cai J, et al · · 2023 · cited 33× · PMID 36818566 · DOI 10.14336/ad.2022.0523
Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives.
Popa IP, Haba MȘC, Mărănducă MA, Tănase DM, et al · · 2022 · cited 11× · PMID 36145711 · DOI 10.3390/pharmaceutics14091964
Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update.
Vaz-Salvador P, Adão R, Vasconcelos I, Leite-Moreira AF, et al · · 2023 · cited 5× · PMID 35098432 · DOI 10.1007/s10557-021-07306-8
Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction.
Ovchinnikov A, Filatova A, Potekhina A, Arefieva T, et al · · 2023 · cited 4× · PMID 37504566 · DOI 10.3390/jcdd10070310

Verify or expand the search:

Other trials of LCZ 696

Trials testing the same drug.

NCT04649229 — Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 · Phase 4 · completed
NCT04113109 — Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 · Phase 4 · completed
NCT03771729 — Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure · EARLY_PHASE1 · unknown
NCT03816306 — Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients · completed
NCT03744975 — PDD in Type 2 Diabetes w/wo Diastolic Dysfunction · Phase 2 · completed

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other National Medical Research Center for Cardiology, Ministry of Health of Russian Federation trials

Trials by the same sponsor.

NCT06655480 — Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF · Phase 2 · not yet recruiting
NCT06683001 — National Heart Failure Registry · recruiting
NCT07452991 — ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With PE · NA · recruiting
NCT06540352 — A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term · Phase 2 · active not recruiting
NCT06683040 — Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension · Phase 2, PHASE3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03928158 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Last refreshed: 25 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03928158.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing